{ "name": "Weight-Loss Drug Trial Results Comparison Dataset", "version": "2026-07-21", "checked": "July 21, 2026", "boundary": "A source-linked orientation dataset of selected reported mean body-weight results from separate clinical trials. Differences in population, duration, dose, route, phase, estimand, adherence assumptions, rescue treatment, missing-data handling, comparator response, and source maturity prevent a cross-trial efficacy or safety ranking. A chart position is not a treatment recommendation, approval, individual prediction, or head-to-head result.", "methodology": "One selected source-linked observation per program and trial formulation. The primary value preserves the source's own active-arm or placebo-adjusted basis. Alternate estimands stay attached to the same record rather than being counted as separate trials. Registry fields are a separate ClinicalTrials.gov snapshot and can differ from a publication's analyzed population.", "stats": { "records": 15, "programs": 13, "trials": 14, "phase3": 7, "oral": 2, "alternateAnalyses": 7, "primarySources": 14, "registryRecords": 14, "minWeeks": 12, "maxWeeks": 80 }, "records": [ { "id": "maritide-phase-2-52-week", "programSlug": "maritide", "program": "MariTide", "aliases": [ "maridebart cafraglutide", "AMG 133" ], "sponsor": "Amgen", "trial": "Phase 2 dose-ranging study", "phase": "Phase 2", "trialId": "NCT05669599", "route": "Monthly injection", "dose": "Upper reported dose-group result", "population": "Adults with obesity or overweight, without type 2 diabetes", "diabetesStatus": "Without type 2 diabetes", "participants": 465, "participantsNote": "Cohort A; 592 adults were enrolled across cohorts A and B", "weeks": 52, "reportedMeanReductionPct": 19.9, "comparatorMeanReductionPct": 2.6, "resultBasis": "Active-arm mean", "estimand": "Efficacy estimand, upper end of the reported dose-group range", "alternateMeanReductionPct": 16.2, "alternateComparatorMeanReductionPct": 2.5, "alternateEstimand": "Treatment-policy estimand, upper end of the reported dose-group range", "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Sponsor topline report", "sourceLabel": "Results from the Phase 2 obesity study of monthly MariTide", "sourcePublisher": "Amgen", "sourceUrl": "https://www.amgen.com/newsroom/press-releases/2025/06/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions", "sourcePublished": "June 23, 2025", "profilePath": "/pipeline/maritide", "note": "The active results were reported as dose-group ranges. This row uses the upper end and keeps the treatment-policy estimate attached as a separate analysis, not a second trial.", "registryUrl": "https://clinicaltrials.gov/study/NCT05669599", "registryStatus": "Completed", "registryLastUpdated": "January 20, 2026", "registryEnrollment": 592, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Quadruple", "maskedParties": [ "Participant", "Care provider", "Investigator", "Outcomes assessor" ], "primaryPurpose": "Treatment" }, { "id": "zenagamtide-oral-phase-1-12-week", "programSlug": "amycretin", "program": "Zenagamtide", "aliases": [ "Amycretin", "NNC0487-0111" ], "sponsor": "Novo Nordisk", "trial": "First-in-human oral multiple-dose cohort", "phase": "Phase 1", "trialId": "NCT05369390", "route": "Daily oral", "dose": "Oral dose reported in the 12-week cohort", "population": "Adults with obesity or overweight", "diabetesStatus": "Early cohort; diabetes status should be checked in the full protocol", "participants": 16, "participantsNote": "Active oral cohort only", "weeks": 12, "reportedMeanReductionPct": 13.1, "comparatorMeanReductionPct": 1.1, "resultBasis": "Active-arm mean", "estimand": "Sponsor-reported exploratory Phase 1 mean", "alternateMeanReductionPct": null, "alternateComparatorMeanReductionPct": null, "alternateEstimand": null, "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Sponsor presentation", "sourceLabel": "Research and early development presentation", "sourcePublisher": "Novo Nordisk", "sourceUrl": "https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P2-Research-and-Early-Development.pdf", "sourcePublished": "March 2024", "profilePath": "/pipeline/amycretin", "note": "The widely repeated 13.1% figure came from 16 active participants over 12 weeks. It is an early signal, not an approved pill or a fair speed comparison with longer trials.", "registryUrl": "https://clinicaltrials.gov/study/NCT05369390", "registryStatus": "Completed", "registryLastUpdated": "June 15, 2025", "registryEnrollment": 144, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Sequential assignment", "studyMasking": "Quadruple", "maskedParties": [ "Participant", "Care provider", "Investigator", "Outcomes assessor" ], "primaryPurpose": "Treatment" }, { "id": "cagrisema-redefine-1-68-week", "programSlug": "cagrisema", "program": "CagriSema", "aliases": [ "cagrilintide plus semaglutide", "REDEFINE 1" ], "sponsor": "Novo Nordisk", "trial": "REDEFINE 1", "phase": "Phase 3", "trialId": "NCT05567796", "route": "Weekly injection", "dose": "Cagrilintide 2.4 mg plus semaglutide 2.4 mg, flexible dosing", "population": "Adults with obesity or overweight and at least one complication", "diabetesStatus": "Without type 2 diabetes", "participants": 3417, "participantsNote": "Total randomized trial population across four arms", "weeks": 68, "reportedMeanReductionPct": 22.7, "comparatorMeanReductionPct": 2.3, "resultBasis": "Active-arm mean", "estimand": "Trial-product estimand", "alternateMeanReductionPct": 20.4, "alternateComparatorMeanReductionPct": 3, "alternateEstimand": "Treatment-policy estimand", "regulatoryStatus": "FDA application under review; not yet approved", "sourceKind": "Peer-reviewed publication", "sourceLabel": "Cagrilintide-semaglutide in adults with overweight or obesity", "sourcePublisher": "PubMed / New England Journal of Medicine", "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/40544433/", "sourcePublished": "June 22, 2025", "profilePath": "/pipeline/cagrisema", "note": "CagriSema is the fixed-dose combination. Its result cannot be reassigned to standalone cagrilintide, semaglutide, or a seller-labelled product.", "registryUrl": "https://clinicaltrials.gov/study/NCT05567796", "registryStatus": "Active, not recruiting", "registryLastUpdated": "July 17, 2026", "registryEnrollment": 3400, "registryEnrollmentType": "Estimated", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Quadruple", "maskedParties": [ "Participant", "Care provider", "Investigator", "Outcomes assessor" ], "primaryPurpose": "Treatment" }, { "id": "cagrilintide-redefine-1-68-week", "programSlug": "cagrilintide", "program": "Cagrilintide", "aliases": [ "AM833", "NNC0174-0833" ], "sponsor": "Novo Nordisk", "trial": "REDEFINE 1 monotherapy arm", "phase": "Phase 3", "trialId": "NCT05567796", "route": "Weekly injection", "dose": "Cagrilintide 2.4 mg, flexible dosing", "population": "Adults with obesity or overweight and at least one complication", "diabetesStatus": "Without type 2 diabetes", "participants": 3417, "participantsNote": "Total randomized trial population; this row represents the cagrilintide arm", "weeks": 68, "reportedMeanReductionPct": 11.8, "comparatorMeanReductionPct": 2.3, "resultBasis": "Active-arm mean", "estimand": "Trial-product estimand", "alternateMeanReductionPct": 11.5, "alternateComparatorMeanReductionPct": 3, "alternateEstimand": "Treatment-policy estimand", "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Peer-reviewed publication", "sourceLabel": "Cagrilintide-semaglutide in adults with overweight or obesity", "sourcePublisher": "PubMed / New England Journal of Medicine", "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/40544433/", "sourcePublished": "June 22, 2025", "profilePath": "/pipeline/cagrilintide", "note": "This is the standalone cagrilintide arm from the same randomized protocol as CagriSema. The combination's result belongs to a different intervention.", "registryUrl": "https://clinicaltrials.gov/study/NCT05567796", "registryStatus": "Active, not recruiting", "registryLastUpdated": "July 17, 2026", "registryEnrollment": 3400, "registryEnrollmentType": "Estimated", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Quadruple", "maskedParties": [ "Participant", "Care provider", "Investigator", "Outcomes assessor" ], "primaryPurpose": "Treatment" }, { "id": "retatrutide-triumph-1-80-week", "programSlug": "retatrutide", "program": "Retatrutide", "aliases": [ "LY3437943", "triple agonist", "reta" ], "sponsor": "Eli Lilly and Company", "trial": "TRIUMPH-1", "phase": "Phase 3", "trialId": "NCT05929066", "route": "Weekly injection", "dose": "12 mg", "population": "Adults with obesity or overweight and at least one complication", "diabetesStatus": "Without diabetes", "participants": 2339, "participantsNote": "Total randomized master-trial population", "weeks": 80, "reportedMeanReductionPct": 28.3, "comparatorMeanReductionPct": 2.2, "resultBasis": "Active-arm mean", "estimand": "Efficacy estimand", "alternateMeanReductionPct": 25, "alternateComparatorMeanReductionPct": 3.9, "alternateEstimand": "Treatment-regimen estimand", "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Sponsor topline report", "sourceLabel": "TRIUMPH-1 Phase 3 topline results", "sourcePublisher": "Eli Lilly and Company", "sourceUrl": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss", "sourcePublished": "May 21, 2026", "profilePath": "/pipeline/retatrutide", "note": "The 28.3% and 25.0% figures answer different analysis questions inside the same trial. Neither creates a head-to-head result against another program.", "registryUrl": "https://clinicaltrials.gov/study/NCT05929066", "registryStatus": "Completed", "registryLastUpdated": "June 3, 2026", "registryEnrollment": 2335, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Double", "maskedParties": [ "Participant", "Investigator" ], "primaryPurpose": "Treatment" }, { "id": "mazdutide-glory-1-48-week", "programSlug": "mazdutide", "program": "Mazdutide", "aliases": [ "IBI362", "LY3305677" ], "sponsor": "Innovent Biologics", "trial": "GLORY-1", "phase": "Phase 3", "trialId": "NCT05607680", "route": "Weekly injection", "dose": "6 mg", "population": "Chinese adults with obesity or overweight", "diabetesStatus": "Without diabetes", "participants": 610, "participantsNote": "Total randomized trial population", "weeks": 48, "reportedMeanReductionPct": 14.01, "comparatorMeanReductionPct": -0.3, "resultBasis": "Active-arm mean", "estimand": "Peer-reviewed trial mean", "alternateMeanReductionPct": null, "alternateComparatorMeanReductionPct": null, "alternateEstimand": null, "regulatoryStatus": "Approved in China for chronic weight management; not FDA approved", "sourceKind": "Peer-reviewed publication", "sourceLabel": "Once-weekly mazdutide in Chinese adults with obesity or overweight", "sourcePublisher": "New England Journal of Medicine", "sourceUrl": "https://www.nejm.org/doi/10.1056/NEJMoa2411528", "sourcePublished": "May 28, 2025", "profilePath": "/pipeline/mazdutide", "note": "The placebo group had a reported 0.30% mean gain, represented here as a negative reduction. China-specific approval does not create FDA approval or worldwide availability.", "registryUrl": "https://clinicaltrials.gov/study/NCT05607680", "registryStatus": "Completed", "registryLastUpdated": "November 12, 2024", "registryEnrollment": 610, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Triple", "maskedParties": [ "Participant", "Care provider", "Investigator" ], "primaryPurpose": "Treatment" }, { "id": "mazdutide-glory-2-60-week", "programSlug": "mazdutide", "program": "Mazdutide", "aliases": [ "IBI362", "LY3305677" ], "sponsor": "Innovent Biologics", "trial": "GLORY-2", "phase": "Phase 3", "trialId": "NCT06164873", "route": "Weekly injection", "dose": "9 mg", "population": "Chinese adults with moderate to severe obesity, with or without type 2 diabetes", "diabetesStatus": "With or without type 2 diabetes", "participants": 461, "participantsNote": "Participants receiving at least one dose; the registry records 462 randomized participants", "weeks": 60, "reportedMeanReductionPct": 16.65, "comparatorMeanReductionPct": 1.5, "resultBasis": "Active-arm mean", "estimand": "Peer-reviewed analysis of participants receiving at least one dose", "alternateMeanReductionPct": null, "alternateComparatorMeanReductionPct": null, "alternateEstimand": null, "regulatoryStatus": "9 mg application under NMPA review in China; not FDA approved", "sourceKind": "Peer-reviewed publication", "sourceLabel": "Mazdutide in Chinese adults with moderate to severe obesity", "sourcePublisher": "PubMed / JAMA", "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/42251595/", "sourcePublished": "June 8, 2026", "profilePath": "/pipeline/mazdutide", "note": "GLORY-2 used a different population, dose, and duration from GLORY-1. Its 9 mg result is not an approved 9 mg label, a US authorization, or a head-to-head ranking against another program.", "registryUrl": "https://clinicaltrials.gov/study/NCT06164873", "registryStatus": "Active, not recruiting", "registryLastUpdated": "August 27, 2024", "registryEnrollment": 462, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Quadruple", "maskedParties": [ "Participant", "Care provider", "Investigator", "Outcomes assessor" ], "primaryPurpose": "Treatment" }, { "id": "enicepatide-ct388-103-48-week", "programSlug": "enicepatide", "program": "Enicepatide", "aliases": [ "CT-388", "RO7795068", "RG6640" ], "sponsor": "Roche / Carmot Therapeutics", "trial": "CT388-103", "phase": "Phase 2", "trialId": "NCT06525935", "route": "Weekly injection", "dose": "24 mg, highest tested dose", "population": "Adults with obesity or overweight and at least one complication", "diabetesStatus": "Without type 2 diabetes", "participants": 469, "participantsNote": "Total randomized dose-finding trial population", "weeks": 48, "reportedMeanReductionPct": 22.5, "comparatorMeanReductionPct": null, "resultBasis": "Placebo-adjusted difference", "estimand": "Placebo-adjusted efficacy estimate", "alternateMeanReductionPct": 18.3, "alternateComparatorMeanReductionPct": null, "alternateEstimand": "Placebo-adjusted treatment-regimen estimate", "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Sponsor topline report", "sourceLabel": "Positive Phase 2 results for CT-388", "sourcePublisher": "Roche", "sourceUrl": "https://www.roche.com/investors/updates/inv-update-2026-01-27", "sourcePublished": "January 27, 2026", "profilePath": "/pipeline/enicepatide", "note": "This result is a placebo-adjusted difference, not the active-arm mean shown for most other rows. Subtracting it from another row would compare unlike measures.", "registryUrl": "https://clinicaltrials.gov/study/NCT06525935", "registryStatus": "Completed", "registryLastUpdated": "April 17, 2026", "registryEnrollment": 469, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Double", "maskedParties": [ "Participant", "Investigator" ], "primaryPurpose": "Treatment" }, { "id": "eloralintide-phase-2-48-week", "programSlug": "eloralintide", "program": "Eloralintide", "aliases": [ "LY3841136", "selective amylin receptor agonist" ], "sponsor": "Eli Lilly and Company", "trial": "Phase 2 obesity trial", "phase": "Phase 2", "trialId": "NCT06230523", "route": "Weekly injection", "dose": "9 mg and 6-to-9 mg strategies", "population": "Adults with obesity or overweight and at least one complication", "diabetesStatus": "Without type 2 diabetes", "participants": 263, "participantsNote": "Total randomized trial population", "weeks": 48, "reportedMeanReductionPct": 20, "comparatorMeanReductionPct": 0.4, "resultBasis": "Active-arm mean", "estimand": "Efficacy estimand, rounded result for two dose strategies", "alternateMeanReductionPct": null, "alternateComparatorMeanReductionPct": null, "alternateEstimand": null, "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Peer-reviewed publication", "sourceLabel": "Eloralintide for obesity or overweight", "sourcePublisher": "PubMed / The Lancet", "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/41207310/", "sourcePublished": "November 7, 2025", "profilePath": "/pipeline/eloralintide", "note": "The publication reported a rounded 20% result for two dose strategies. It is not evidence that every participant lost 20% or that the program outperformed a separate trial.", "registryUrl": "https://clinicaltrials.gov/study/NCT06230523", "registryStatus": "Completed", "registryLastUpdated": "June 24, 2026", "registryEnrollment": 263, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Double", "maskedParties": [ "Participant", "Investigator" ], "primaryPurpose": "Treatment" }, { "id": "petrelintide-zupreme-1-42-week", "programSlug": "petrelintide", "program": "Petrelintide", "aliases": [ "ZP8396", "long-acting amylin analogue" ], "sponsor": "Zealand Pharma + Roche", "trial": "ZUPREME-1", "phase": "Phase 2", "trialId": "NCT06662539", "route": "Weekly injection", "dose": "Upper reported dose-group result", "population": "Adults with obesity or overweight and weight-related complications", "diabetesStatus": "Without type 2 diabetes", "participants": 493, "participantsNote": "Total randomized trial population", "weeks": 42, "reportedMeanReductionPct": 10.7, "comparatorMeanReductionPct": 1.7, "resultBasis": "Active-arm mean", "estimand": "Efficacy estimand, upper end of five dose-group estimates", "alternateMeanReductionPct": null, "alternateComparatorMeanReductionPct": null, "alternateEstimand": null, "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Sponsor topline report", "sourceLabel": "Positive Phase 2 results for petrelintide", "sourcePublisher": "Roche", "sourceUrl": "https://www.roche.com/media/releases/med-cor-2026-03-05", "sourcePublished": "March 5, 2026", "profilePath": "/pipeline/petrelintide", "note": "The active results were dose-group estimates. The row uses the upper reported value and does not convert a tolerability headline into a safety ranking.", "registryUrl": "https://clinicaltrials.gov/study/NCT06662539", "registryStatus": "Completed", "registryLastUpdated": "March 23, 2026", "registryEnrollment": 493, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Double", "maskedParties": [ "Participant", "Investigator" ], "primaryPurpose": "Treatment" }, { "id": "survodutide-synchronize-1-76-week", "programSlug": "survodutide", "program": "Survodutide", "aliases": [ "BI 456906", "GLP-1/glucagon dual agonist" ], "sponsor": "Boehringer Ingelheim + Zealand Pharma", "trial": "SYNCHRONIZE-1", "phase": "Phase 3", "trialId": "NCT06066515", "route": "Weekly injection", "dose": "6 mg, upper reported result", "population": "Adults with obesity or overweight", "diabetesStatus": "Without type 2 diabetes", "participants": 726, "participantsNote": "Actual enrollment in the completed trial record", "weeks": 76, "reportedMeanReductionPct": 16.6, "comparatorMeanReductionPct": 3.2, "resultBasis": "Active-arm mean", "estimand": "Efficacy estimand, upper reported result", "alternateMeanReductionPct": 13, "alternateComparatorMeanReductionPct": null, "alternateEstimand": "Treatment-regimen estimand", "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Peer-reviewed publication", "sourceLabel": "Survodutide once weekly for adults with obesity", "sourcePublisher": "PubMed / New England Journal of Medicine", "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/42253238/", "sourcePublished": "June 7, 2026", "profilePath": "/pipeline/survodutide", "note": "The 16.6% weight result and separate liver-fat findings answer different endpoints. Neither produces a cross-program winner or a personal outcome estimate.", "registryUrl": "https://clinicaltrials.gov/study/NCT06066515", "registryStatus": "Completed", "registryLastUpdated": "March 12, 2026", "registryEnrollment": 726, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Quadruple", "maskedParties": [ "Participant", "Care provider", "Investigator", "Outcomes assessor" ], "primaryPurpose": "Treatment" }, { "id": "vk2735-venture-injectable-13-week", "programSlug": "vk2735", "program": "VK2735 injection", "aliases": [ "Viking VK2735", "VENTURE injectable" ], "sponsor": "Viking Therapeutics", "trial": "VENTURE", "phase": "Phase 2", "trialId": "NCT06068946", "route": "Weekly injection", "dose": "15 mg", "population": "Adults with obesity or overweight and at least one complication", "diabetesStatus": "Without diabetes", "participants": 176, "participantsNote": "Total randomized trial population", "weeks": 13, "reportedMeanReductionPct": 14.7, "comparatorMeanReductionPct": 1.7, "resultBasis": "Active-arm mean", "estimand": "Peer-reviewed 13-week mean", "alternateMeanReductionPct": null, "alternateComparatorMeanReductionPct": null, "alternateEstimand": null, "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Peer-reviewed publication", "sourceLabel": "Weekly subcutaneous VK2735 Phase 2 publication", "sourcePublisher": "PubMed / Obesity", "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/41508550/", "sourcePublished": "January 8, 2026", "profilePath": "/pipeline/vk2735", "note": "The 13-week result is a short-duration dose-finding observation. Dividing it into a weekly rate would ignore escalation, plateau timing, and discontinuation.", "registryUrl": "https://clinicaltrials.gov/study/NCT06068946", "registryStatus": "Completed", "registryLastUpdated": "February 12, 2025", "registryEnrollment": 176, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Triple", "maskedParties": [ "Participant", "Care provider", "Investigator" ], "primaryPurpose": "Treatment" }, { "id": "vk2735-venture-oral-13-week", "programSlug": "vk2735", "program": "VK2735 oral", "aliases": [ "Oral VK2735", "VENTURE-Oral" ], "sponsor": "Viking Therapeutics", "trial": "VENTURE-Oral", "phase": "Phase 2", "trialId": "NCT06828055", "route": "Daily oral", "dose": "120 mg", "population": "Adults with obesity or overweight and at least one complication", "diabetesStatus": "Without diabetes", "participants": 280, "participantsNote": "Total randomized trial population", "weeks": 13, "reportedMeanReductionPct": 12.2, "comparatorMeanReductionPct": 1.3, "resultBasis": "Active-arm mean", "estimand": "Sponsor-reported 13-week mean", "alternateMeanReductionPct": null, "alternateComparatorMeanReductionPct": null, "alternateEstimand": null, "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Sponsor topline report", "sourceLabel": "VENTURE-Oral Phase 2 results", "sourcePublisher": "Viking Therapeutics", "sourceUrl": "https://ir.vikingtherapeutics.com/2026-05-12-Viking-Therapeutics-Presents-Data-from-its-13-Week-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-at-European-Congress-on-Obesity-ECO-2026", "sourcePublished": "May 12, 2026", "profilePath": "/pipeline/vk2735", "note": "The oral and injected VK2735 rows come from separate trials. Matching durations do not make their formulations, doses, adherence, or tolerability directly interchangeable.", "registryUrl": "https://clinicaltrials.gov/study/NCT06828055", "registryStatus": "Completed", "registryLastUpdated": "October 6, 2025", "registryEnrollment": 280, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Triple", "maskedParties": [ "Participant", "Care provider", "Investigator" ], "primaryPurpose": "Treatment" }, { "id": "ecnoglutide-slimmer-48-week", "programSlug": "ecnoglutide", "program": "Ecnoglutide", "aliases": [ "XW003", "Sciwind ecnoglutide", "埃诺格鲁肽" ], "sponsor": "Sciwind Biosciences", "trial": "SLIMMER", "phase": "Phase 3", "trialId": "NCT05813795", "route": "Weekly injection", "dose": "2.4 mg", "population": "Chinese adults with obesity or overweight", "diabetesStatus": "Without diabetes", "participants": 664, "participantsNote": "Total randomized trial population", "weeks": 48, "reportedMeanReductionPct": 15.4, "comparatorMeanReductionPct": 0.3, "resultBasis": "Active-arm mean", "estimand": "Treatment-policy estimand", "alternateMeanReductionPct": 15.1, "alternateComparatorMeanReductionPct": null, "alternateEstimand": "Placebo-adjusted difference", "regulatoryStatus": "Approved in China for chronic weight management; not FDA approved", "sourceKind": "Sponsor topline report", "sourceLabel": "SLIMMER week-48 Phase 3 results", "sourcePublisher": "Sciwind Biosciences", "sourceUrl": "https://www.sciwindbio.com/portal/index/newsdetail/id/125/category_id/5.html", "sourcePublished": "March 6, 2026", "profilePath": "/pipeline/ecnoglutide", "note": "The 15.4% active-arm mean and 15.1% placebo-adjusted difference are different measures. China approval does not establish FDA approval or access in another country.", "registryUrl": "https://clinicaltrials.gov/study/NCT05813795", "registryStatus": "Completed", "registryLastUpdated": "April 30, 2025", "registryEnrollment": 664, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Triple", "maskedParties": [ "Participant", "Care provider", "Investigator" ], "primaryPurpose": "Treatment" }, { "id": "pemvidutide-momentum-48-week", "programSlug": "pemvidutide", "program": "Pemvidutide", "aliases": [ "ALT-801", "balanced GLP-1/glucagon dual agonist" ], "sponsor": "Altimmune", "trial": "MOMENTUM", "phase": "Phase 2", "trialId": "NCT05295875", "route": "Weekly injection", "dose": "2.4 mg", "population": "Adults with obesity, or overweight plus a comorbidity", "diabetesStatus": "Without diabetes", "participants": 391, "participantsNote": "Total randomized trial population", "weeks": 48, "reportedMeanReductionPct": 15.6, "comparatorMeanReductionPct": 2.2, "resultBasis": "Active-arm mean", "estimand": "Sponsor-reported 48-week mean", "alternateMeanReductionPct": null, "alternateComparatorMeanReductionPct": null, "alternateEstimand": null, "regulatoryStatus": "Investigational; not FDA approved", "sourceKind": "Sponsor topline report", "sourceLabel": "MOMENTUM 48-week obesity results", "sourcePublisher": "Altimmune", "sourceUrl": "https://ir.altimmune.com/news-releases/news-release-details/altimmune-presents-data-phase-2-momentum-trial-pemvidutide", "sourcePublished": "June 23, 2024", "profilePath": "/pipeline/pemvidutide", "note": "MOMENTUM was a Phase 2 obesity trial. The result does not establish an approved dose, a Phase 3 outcome, or a direct comparison with another program.", "registryUrl": "https://clinicaltrials.gov/study/NCT05295875", "registryStatus": "Completed", "registryLastUpdated": "November 29, 2023", "registryEnrollment": 391, "registryEnrollmentType": "Actual", "studyAllocation": "Randomized", "studyInterventionModel": "Parallel assignment", "studyMasking": "Double", "maskedParties": [ "Participant", "Investigator" ], "primaryPurpose": "Treatment" } ] }